Search Results - "Flaujac, C"

Perioperative management and neuraxial analgesia in women with factor XI deficiency (<60 IU/dL): a French multicenter observational study of 314 pregnancies by Flaujac, C., Faille, D., Lavenu-Bombled, C., Drillaud, N., Lasne, D., Billoir, P., Desconclois, C., Touzet, L., Lebreton, A., Diaz-Cau, I., d’Oiron, R., Giansily-Blaizot, M., Wibaut, B., Beurrier, P., Volot, F., Rugeri, L., Roussel-Robert, V., de Raucourt, E.

“…Factor (F)XI deficiency is a rare bleeding disorder with a poor correlation between bleeding tendency and FXI level. Management of pregnant women with FXI…”
Get full text

C0551: Homozygous Protein C Deficiency with Late Clinical Onset. Long-Term Follow-Up in 4 Patients by Conard, J, Combe, S, Horellou, M.H, Flaujac, C, Samama, M.M

Get full text

Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia? by Barré, A., Dréanic, J., Flaujac, C., Roussel-Robert, V., Stieltjes, N., Combe-Marzelle, S., Coriat, R., Horellou, MH

Get full text

Agreement between factor XIII activity and antigen assays in measurement of factor XIII: A French multicenter study of 147 human plasma samples by Caron, C., Meley, R., Le Cam Duchez, V., Aillaud, M. F., Lavenu‐Bombled, C., Dutrillaux, F., Flaujac, C., Ryman, A., Ternisien, C., Lasne, D., Galinat, H., Pouplard, C.

“…Summary Introduction Factor XIII (FXIII) deficiency is a rare hemorrhagic disorder whose early diagnosis is crucial for appropriate treatment and prophylactic…”
Get full text

A vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with vitamin K antagonist resistance by BODIN, L., HORELLOU, M. H., FLAUJAC, C., LORIOT, M. A., SAMAMA, M. M.

Get full text

Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists by Cambus, J P, Magnin, D, Ambid-Lacombe, C, Bura, A, Desgrippes, F, Schneller, J M, Benhamou, Y, Flaujac, C, Horellou, M H, De Raucourt, E, Kaczan, D, Astoul, J M, Siguret, V

“…Recent data show that the quality of anticoagulation evaluated in patients receiving vitamin K antagonists (VKA) is not optimal in France. The aim of this…”
Get full text

Skin necrosis due to fluindione treatment: a rare but serious complication by Beqqal, K., Horellou, M.H., Philippe, A., Gelas, M. Alhene, Flaujac, C., Gorin, I., Jacobelli, S., Dupin, N., Hassam, B., Avril, M.F.

“…In the setting of protein C deficiency, skin necrosis, which occurs most often at the initial phase of oral anticoagulants therapy, is a rare side effect. Six…”
Get full text

Atypical mutations of the prothrombin gene at positions 20 209 and 20 218, and a novel mutation at position 20 219. Report on 10 patients by FLAUJAC, C., CONARD, J., HORELLOU, M. H., LE FLEM, L., SAMAMA, M. M.

Get full text

Impact de la contraception hormonale sur les caractéristiques des évènements thromboemboliques veineux des 3072 femmes de la cohorte française COntraception and REcurrentVenous Event (COREVE) by Hugon-Rodin, J., Dr, Horellou, M.H., Dr, Conard, J., Dr, Flaujac, C., Dr, Scarabin, P.Y., Dr, Plu-Bureau, G., Pr

“…Objectif Évaluation des caractéristiques cliniques et biologiques des femmes lors d’un 1er évènement thromboembolique veineux (ETV), et du pourcentage d’ETV…”
Get full text

Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases by Berezné, A., Stieltjes, N., Le‐Guern, V., Teixeira, L., Billy, C., Roussel‐Robert, V., Flaujac, C., Horellou, M.‐H., Guillevin, L., Mouthon, L.

“…Acquired haemophilia is a factor VIII (FVIII) deficiency due to autoantibodies directed against FVIII that can be responsible for severe haemorrhage. The…”
Get full text

Review: delta-storage pool disease by Masliah-Planchon, J, Flaujac, C, Tapon-Bretaudière, J, Cramer-Bordé, E M, Darnige, L

“…Platelet storage pool disease is a qualitative platelet disorder associated with variable degrees of reduction in the numbers and contents of dense granules…”
Get more information

Les cliniques d’anticoagulants sont-elles efficaces en France ? Évaluation des performances de six cliniques dans la gestion des traitements par antivitamines K by Cambus, J.P., Magnin, D., Ambid-Lacombe, C., Bura, A., Desgrippes, F., Schneller, J.M., Benhamou, Y., Flaujac, C., Horellou, M.H., De Raucourt, E., Kaczan, D., Astoul, J.M., Siguret, V.

“…Plusieurs données récentes montrent que la qualité de l’anticoagulation des patients traités par les antivitamines K (AVK) n’est pas optimale en France. Le but…”
Get full text

PB0491 Patients from Different Settings Receiving Unfractionated Heparin (DEXHEP Study): Impact of PF4 on Anti-Xa Levels by Savard, P., Curis, E., Gouin-Thibault, I., Toussaint-Hacquard, M., Delassasseigne, C., Bauters, A., Flaujac, C., Eschewege, V., Mouton, C., Lecompte, T., De Maistre, E., Lasne, D., Siguret, V.

Get full text

Pharmacologic heterogeneity of new anticoagulants by Samamaa, M-M, Conard, J, Flaujac, C, Combe, S, Horellou, M-H

“…Amongst numerous promising anticoagulant molecules, rivaroxaban (Xarelto(®)), dabigatran (Pradaxa(®)) and apixaban (Eliquis(®)) have been registered outside…”
Get more information

D’inhabituels et volumineux hématomes chez une jeune patiente atteinte d’un lupus érythémateux systémique by Hua, C., Meni, C., See, H., Lasnes, D., Flaujac, C., Borgel, D., Bader-Meunier, B., Bodemer, C.

“…Le déficit acquis en facteur XIII est rare mais grave avec un risque hémorragique fatal (29 %). Il est lié à l’acquisition d’un auto-anticorps inhibiteur…”
Get full text

EVALUATION OF A NEW FUNCTIONAL CLOTTING ASSAY FOR THE MONITORING OF HEPARIN AND HEPARINOID ANTICOAGULANTS BASED ON THROMBIN AND/OR FACTOR XA INHIBITION WITH CLINICAL PATIENT PLASMAS AT THREE UNIVERSITY MEDICAL CENTERS by Schöni, R., Walenga, J., Samama, M., Harenberg, J., Drenth, A.F., le Courvoisier-Flaujac, C., Giese, C., Rudin, K., Bühler, B., Wilmer, M.

Get full text

Hétérogénéité pharmacologique des nouveaux anticoagulants: Nouveaux traitements de la maladie veineuse thrombo-embolique. 45e Congrès du Collège Français de Pathologie Vasculaire (CFPV) by SAMAMA, M.-M, CONARD, J, FLAUJAC, C, COMBE, S, HORELLOU, M.-H

Get full text

Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia? by Barré, A, Dréanic, J, Flaujac, C, Roussel-Robert, V, Stieltjes, N, Combe-Marzelle, S, Coriat, R, Horellou, Mh

Get full text

Concordance entre les tests globaux (TP, TCA et TT) et les activités anticoagulantes spécifiques du rivaroxaban et du dabigatran by Ibrahim, F., Layka, A., Gouin-Thibault, I., Horellou, M.-H., Mazoyer, E., Flaujac, C.

Get full text

Le ROTEM® n’est pas approprié pour apprécier le risque hémorragique du patient cirrhotique by Lentschener, C., LeCourvoisier Flaujac, C., Firas, I., Gouin, I., Bazin, M., Samama, C.M.

“…Le ROTEM® a été associé à une réduction significative des pertes sanguines et des besoins transfusionnels en chirurgie cardiaque, chez les traumatisés, en…”
Get full text